Pfizer CEO: Allergan deal is ‘a lot more about growth’ than job cuts

Carly Helfand Anyone who's examined Pfizer's job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. But this time? Things will ...

GSK whistleblower claims to have been fired after emailing CEO about Nicoderm concerns

Eric Palmer GlaxoSmithKline's Nicoderm products are among the leaders in helping smokers kick their habits. But a former employee says the study that showed their edge over ...

What can Gilead, Biogen and Celgene teach Big Pharma about R&D?

John Carroll For the past 5 years the biopharma experts at Deloitte have been keeping an eye on a disturbing trend that shows no sign of letting up anytime soon. The biggest players ...

Why is Novartis’ Copaxone copy lagging? It’s all about coverage, analyst explains

Carly Helfand Typically, the first generics for blockbuster meds get off to a running start. Not so with Novartis' generic of Teva's multiple sclerosis standout Copaxone, though–and ...

More grist for PCSK9 fight as Amgen sets up EU to pay about half as much as U.S.

Tracy Staton Last week, Amgen won its much-anticipated FDA approval for the PCSK9 cholesterol-fighter Repatha and promptly set a price of $ 14,100 per year. But even after pharmacy ...

Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

John Carroll Shire has been quiet since making its unwelcomed $ 30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step ...

Actavis talks to DOJ about resolving probe of Warner Chilcott marketing misdeeds

Eric Palmer Actavis is trying to rid itself of some nasty legal entanglements that it picked up in its $ 8.5 billion deal for Ireland's Warner Chilcott, meeting with the Justice ...

Judge’s ‘serious questions’ about Ackman trading in Allergan may fire SEC into action

Carly Helfand Valeant partner and leading Allergan shareholder Bill Ackman may have won the right to vote his shares at a Dec. 18 special meeting, at which he hopes to upturn Allergan's ...

AstraZeneca crows about Brilinta edge in new ACS treatment guidelines

Tracy Staton Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really ...

Don’t worry about a hep C pricing war, analysts tell Gilead-watchers

Tracy Staton No price war on hepatitis C drugs? That would be a disappointment to payers worried about the cost of treating millions of patients with super-expensive, yet highly effective ...

When will Big Pharma get serious about antibiotic R&D?

Damian Garde The 5 most promising antibiotic treatments in the industry's pipeline all have something in common: Not one was developed by Big Pharma. FierceBiotech News

AstraZeneca shareholders pitch a fit about pay

Eric Palmer AstraZeneca CEO Pascal Soriot saw his pay fall last year along with the company's fortunes but that didn't keep large blocks of shareholders from displaying their ...
© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS